Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Walter K. Kraft
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or non-pregnant female \>/=18 and \</=65 years of age at the time of consent
Laboratory confirmed SARS-CoV-2 infection
Investigator-estimated hospitalization duration of at least 5 days
You may not be if
Need for \>4 liters nasal cannula oxygen to maintain oxygen saturation \>90%
Hypersensitivity to sirolimus
Pregnant or breastfeeding
Anticipated transfer to another study hospital within 72 hours
Alanine transaminase (ALT) \>3 times the upper limit of normal
Creatinine clearance \<30mL/min as estimated by Cockcroft-Gault
Underlying immunosuppression due to daily \>5 mg prednisone equivalent a day, prior solid organ transplant, or other immunosuppression deemed by investigator to be potentially unsafe
Co-administration with strong inhibitors of CYP3A4 and/or P-glycoprotein (P-gp) (such as ketoconazole, voriconazole, itraconazole, telithromycin, clarithromycin and others)
Co-administration with strong inducers of CYP3A4 and/or P-glycoprotein (P-gp) (such as phenytoin or rifampin)
Anticipated surgery within 1 month
Need for healing of a fracture or a significant soft tissue wound
